Precision BioSciences DSMB Clears Additional PBGENE-DMD Dosing
The independent DSMB found no safety concerns after reviewing the first treated patient in the Phase 1/2 study.
The independent DSMB found no safety concerns after reviewing the first treated patient in the Phase 1/2 study.